Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» TCR2 Therapeutics
TCR2 Therapeutics
Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline
Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline
Fierce Biotech
Adaptimmune Therapeutics
TCR2 Therapeutics
M&A
Flag link:
Layoffs continue to batter biotech, with Big Pharmas piling on the pain
Layoffs continue to batter biotech, with Big Pharmas piling on the pain
Fierce Biotech
layoffs
Amgen
Merck KGaA
TCR2 Therapeutics
Moderna Therapeutics
Flag link:
ESMO Preview: Highlights to Watch for This Year
ESMO Preview: Highlights to Watch for This Year
BioSpace
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
Flag link:
TCR² releases early data from some PhI patients, sparking optimism from analysts
TCR² releases early data from some PhI patients, sparking optimism from analysts
Endpoints
TCR2 Therapeutics
clinical trials
t cell therapy
Flag link:
Immuno-Oncology Company Plans $92 Million IPO
Immuno-Oncology Company Plans $92 Million IPO
CP Wire
TCR2 Therapeutics
immuno-oncology
IPOs
Flag link:
Immuno-Oncology Company Plans $92 Million IPO
TCR2 Therapeutics
immuno-oncology
IPOs
Flag link:
TCR2 Shoots for $100 Million IPO in Early 2019
TCR2 Shoots for $100 Million IPO in Early 2019
BioSpace
TCR2 Therapeutics
IPOs
CAR-T
Flag link:
